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Background. Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria. Initially
conﬁned to parts of Indonesia and Papua, resistance of P. vivax to CQ seems to be spreading, and alternative
treatments are required.
Methods. We conducted a randomized controlled study to compare the efﬁcacy and the tolerability of CQ and
dihydroartemisinin-piperaquine (DP) in 500 adults and children with acute vivax malaria on the Northwestern
border of Thailand.
Results. Both drugs were well tolerated. Fever and parasite clearance times were slower in the CQ than in the DP
group (P , .001). By day 28, recurrent infections had emerged in 18 of 207 CQ recipients compared with 5 of 230
treated with DP (relative risk, 4.0; 95% conﬁdence interval [CI], 1.51–10.58; P 5 .0046). The cumulative risk of
recurrence with P. vivax at 9 weeks was 79.1% (95% CI, 73.5%–84.8%) in patients treated with CQ compared with
54.9% (95% CI, 48.2%–61.6%) in those receiving DP (hazard ratio [HR], 2.27; 95% CI, 1.8–2.9; P , .001). Children
,5 years old were at greater risk of recurrent P. vivax infection (74.4%; 95% CI, 63.2%–85.6%) than older patients
(55.3% [95% CI, 50.2%–60.4%]; HR, 1.58 [95% CI, 1.1–2.2]; P 5 .005). In vitro susceptibility testing showed that
13% of the tested isolates had a CQ median inhibitory concentration .100 nmol/L, suggesting reduced susceptibility.
Conclusions. The efﬁcacy of CQ in the treatment of P. vivax infections is declining on the Thai-Myanmar
border. DP is an effective alternative treatment.
Clinical Trials Registration. ISRCTN87827353.
Chloroquine (CQ) remains the drug of choice for
the prevention and treatment of infections caused by
Plasmodium vivax in most endemic regions, although
the decline in the efﬁcacy of CQ may have been over-
looked [1, 2]. CQ-resistant P. vivax was ﬁrst described
in 1989 in Papua New Guinea [3]. For several years,
reports of reduced CQ efﬁcacy were limited to the
island of New Guinea [4–6]. The degree of CQ re-
sistance in Papua, Indonesia and Papua New Guinea
has now become so severe that local antimalarial
treatment policies have been revised to adopt arte-
misinin combination therapy for both Plasmodium
falciparum and P. vivax infections. More recently,
CQ-resistant P. vivax has been documented across
the Indonesian archipelago [1] and in Myanmar [7, 8],
South Korea [9], Turkey [10], the Horn of Africa [11],
and South America [12].
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with Cambodia and Myanmar, where multidrug-resistant
P. falciparum is endemic. In 1996, in camps for displaced per-
sons of the Karen ethnic minority on the Northwestern border
of Thailand, we found that CQ was a highly effective treatment
for P. vivax malaria, with ,3% of patients having a recurrence
(relapse, reinfection or recrudescence) by day 28 [13]. However,
in a study conducted 7 years later in neighboring Myanmar,
almost 35% of treated patients had a parasite recurrence by day
28, raising the possibility that resistance was spreading along the
Thai-Myanmar border [7]. In addition, in vitro sensitivity
testing on fresh parasite isolates collected between 2003 and
2007 in the same region indicated a decreased susceptibility to
CQinsomeisolates[14].PatientswithCQ-resistantP.vivax can
be treated effectively with the dihydroartemisinin-piperaquine
combination (DP) as well as other artemisinin combination
therapies[2,5,15]. To reassess the efﬁcacy of CQ in the treatment
of P. vivax infections on the Northwestern border of Thailand
and study the efﬁcacy of DP, we conducted a randomized
controlled trial in patients with P. vivax monoinfections.
METHODS
Patients
The study took place in the Shoklo Malaria Research Unitclinics
on the Thailand-Myanmar border, an area of low (entomologic
inoculation rate, ,1) and seasonal malaria transmission[16].
Patients .1 year old and with a body weight of $5k gw e r e
eligible for enrollment if they had a microscopically conﬁrmed
monoinfection of P. vivax (parasitemia, $5/500 white blood
cells), if they were febrile(axillary temperature,$37.5C) or had
a history of fever, and if they or their guardians gave fully in-
formed consent. Patients were excluded if they had a known
hypersensitivity to the study drugs; had intercurrent illness or
were pregnant, lactating, or severely anemic (hematocrit,
,20%); or had received meﬂoquine treatment in the previous
60 days or DP in the previous 3 months.
Randomization
Patients were allocated to the treatment arms based on a pre-
generated randomization list in blocks of 20. The individual
allocations were concealed in sealed envelopes and opened only
after enrollment by the ﬁeld team. Although patients and clinic
workers were not blinded to the treatment arm after allocation,
laboratory technicians were unaware of treatment allocation.
Drugs
Chloroquine (Government Pharmaceutical Organization,
Thailand) was given once a day for 3 days, with a target dose of
25 mg base/kg with a glass of water. DP (Duocotexin; Holley
People’s Republic of China) was administered once a day for
3 days with milk, with a total target dose of 7 mg/kg for dihy-
droartemisinin and 55 mg/kg for piperaquine. All patients with
a normal G6PD test result were offered a course of 14 days of
primaquine (0.5 mg base/kg/d) at the end of the follow-up
period. This delay was instituted because primaquine itself is
active against asexual stages of P. vivax [17] and its adminis-
tration earlier would have compromised the analysis of the
efﬁcacy of CQ and DP.
Enrollment Procedures
A case-record form was completed for all patients documenting
symptoms before clinic attendance, concomitant illness, drug
history and physical examination. Capillary blood was collected
formalariathickandthinﬁlms,hematocrit,andG6PDdeﬁciency
testing. Patients .1 year of age presenting with parasitemia of
.100 P. vivax trophozoites/500 white blood cells were asked to
provide 5 mL of venous blood for in vitro sensitivity testing.
Follow-up
Patients were seen daily from admission until they were afebrile
and aparasitemic and then weekly until day 63. At each visit,
temperature was measured and a symptom questionnaire was
completed. Capillary blood was taken for malaria blood smear
and hematocrit weekly. Any concomitant medication taken
during the study period was recorded. Patients presenting to the
clinic within the follow-up period with microscopically con-
ﬁrmed P. vivax had capillary blood sampling for measurement
of CQ and desethylchloroquine plasma concentrations. Patients
with P. falciparum infection diagnosed during the follow-up
period were withdrawn from the study and treated with the
standard 3-day treatment of meﬂoquine and artesunate.
Drug Measurements
CQ and desethylchloroquine plasma concentrations were mea-
sured in patients .10 years old at the time of recurrent malaria.
Plasma drug concentrations were quantiﬁed using solid-phase
extraction and high-performance liquidchromatography with UV
detection [18]. The limit of detection was 1 ng/mL for both drugs.
Laboratory Methods
Malaria blood ﬁlms were stained with Giemsa, and parasite
counts were expressed as the number of parasites per 1000 red
blood cells or, if the parasitemia was ,1% packed red blood
cells, as the number of parasites per 500 white blood cells. G6PD
deﬁciency was assessed by the ﬂuorescent spot test SQMMR500
(R&D Diagnostic). In vitro samples for drug susceptibility were
processed and analyzed as described elsewhere [14].
Study End Points
The analysis of efﬁcacy was conducted using a modiﬁed
intention-to-treat analysisthat includedall patientswho fulﬁlled
the enrollment criteria. The primary end point was the overall
risk of recurrence with P. vivax during the 63-day follow-up
978 d CID 2011:53 (15 November) d Phyo et alperiod. Secondary end points included the risk of reappearance
of P. falciparum, the parasite and fever clearance times, and the
adverse events reported by the patients.
Sample Size
The original sample size of 500 patients had 80% power and
95% conﬁdence to detect a 15% difference in the primary end
point, assuming a 50% recurrence rate in the CQ group,
allowing for up to 15% loss to follow-up by day 63.
Statistical Analysis
Data were double entered into Microsoft Access software and
analysis was performed using SPSS for Windows (version 16;
SPSS). The Mann–Whitney U test was used for nonparametric
comparisons, and Student t test or 1-way analysis of variance for
parametric comparisons. Proportions were examined using v
2
with Yates’ correction or by Fisher’s exact test. Efﬁcacy end
pointswereassessedbysurvivalanalysis,inwhichthecumulative
risk of failure was calculated by the Kaplan–Meier product limit
formula and compared by the Mantel–Haenszel log-rank test. In
addition, treatments were compared and the hazard ratio (HR)
calculated using a Cox proportional hazards model. Data were
censored for patients who were unavailable for follow-up or, in
the caseofsecondaryend points, presented againwitha different
outcome and not regarded as treatment failures. Those patients
with recurrent vomiting or adverse drug effects, which required
early termination of treatment and the administration of rescue
therapy, were regarded as therapeutic failures.
Ethical Approval
The study was approved by the Ethics Committee of the Faculty
of Tropical Medicine, Mahidol University (MUTM 2006-029),
and the Oxford Tropical Research Ethics Committee, Oxford
University (OXTREC 027-05). The trial was registered at
ClinicalTrials.gov (ISRCTN87827353).
RESULTS
Recruitment and Baseline Characteristics
Between January 2007 and December 2008, 500 patients were
enrolled in the study. Eight of these patients did not meet the
inclusion criteria and were excluded from further analysis
(Figure 1). The baseline characteristics of the 492 patients in the
evaluable population (modiﬁed intention-to-treat analysis) are
presented in Table 1; there were no differences in baseline
characteristics between treatment arms. Follow-up to day 63 or
day of failure (per-protocol analysis) was achieved in 86.7% of
Figure 1. Study profile.
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CQ (P 5 .95). Nonadherence to follow-up was more likely in
adults (16%; 47/291) than in children (8.5%; 17/201; P 5 .01),
but these patients otherwise had similar baseline characteristics
as those who were adherent to follow-up. With the exception of
a 3-year old boy who vomited CQ repeatedly, there were no
other early treatment failures. In patients receiving a complete
course of treatment, the median dose of CQ administered in the
CQ arm was 24.8 mg base/kg (range, 21.3–29.4), and patients in
the DP arm received median doses of 6.7 mg/kg (range, 5–10)
of dihydroartemisinin and 53.3 mg/kg (range, 40–80) of
piperaquine.
Early Therapeutic Response
Within 24 hours after the start of treatment, 63.7% of patients
(156/245) receiving DP had clearance of asexual parasitemia
after, compared with only 21.1% (51/242) receiving CQ (odds
ratio, 6.6; 95% conﬁdence interval [CI], 4.3–10.0; P , .001).
After 48 hours, these proportions had risen to 97.5% (237/243)
and 84.1% (201/239), respectively (P , .001). Five patients
treated with CQ were still parasitemic at 72 hours, and all but
1 had cleared by 96 hours. In the CQ but not in the DP group,
patients with schizont stages present at enrollment were more
likely to be parasitemic at 24 hours than were patients with
only trophozoite asexual stages present (93% [69/74] vs 72.6%
[122/168], respectively; odds ratio, 5.2; 95% CI, 1.9–15.7;
Table 1. Patient Characteristics at Baseline
a
Characteristic DP treatment (n 5 248) CQ treatment (n 5 244)
Asexual parasitemia, geometric mean (95% CI), lL
21 3776 (3111–4582) 4406 (3637–5339)
Gametocytemia, geometric mean (95% CI), lL
21 214 (178–257) 280 (236–333)
Gametocytemia present 85 (210) 84 (205)
Schizonts present at enrollment 32 (79) 30 (74)
Male sex 70 (173) 64 (155)
G6PD deﬁciency 6.1 (15/247) 5.3 (13)
Weight, median (range), kg 45 (7–74) 45 (9–61)
Age, median (range), years 18 (1–57) 18 (1–63)
Age, years
,5 14 (34) 12 (30)
5–14 27 (67) 29 (70)
.14 59 (147) 59 (144)
Fever .38.0C 42 (94/225) 42 (97/229)
Duration of febrile illness, median (range), days 2 (0–8) 2 (0–5)
Hematocrit, mean (SD), % 37.2 (5.0) 37.6 (5.2)
Anemia (hematocrit ,30%) 4.5 (11/247) 5.8 (14/242)
Splenomegaly 14 (34/243) 12 (29/237)
Hepatomegaly 23 (57/247) 26 (63)
Abbreviations: CI, conﬁdence interval; CQ, chloroquine; DP, dihydroartemisinin-piperaquine; SD, standard deviation.
a Unless otherwise indicated, data represent % (No.) of patients, with denominators where these were smaller than the full sample.
Table 2. Risk of Treatment Failure: Modified Intention-to-Treat Analysis
Cumulative risk of recurrence
a (95% CI), %




c 54.9 (48.2–61.6) 79.1 (73.4–84.8) 2.27 (1.8–2.9) (P , .001)
Day 28
d 4.1 (1.6–6.6) 9.8 (5.9–13.7) 2.3 (1.1–4.9) (P 5 .032)
Plasmodium falciparum
Day 63
d 8.0 (4.5–11.5) 11.5 (6.6–16.4) 1.5 (0.8–2.9) (P 5 .176)
Day 28
d 2.4 (0.4–4.4) 7.8 (4.3–11.3) 3.1 (1.2–7.9) (P 5. 015)
Abbreviations: CI, conﬁdence interval; CQ, chloroquine; DP, dihydroartemisinin-piperaquine.
a Cumulative risk calculated by Kaplan-Meier method. Patients with an incomplete course of treatment were included in the analysis conservatively as treatment
failures; other patients with incomplete follow-up were censored on the last day of follow-up as nonfailures.
b Hazard ratios were calculated using a Cox proportional hazards model.
c Primary end point.
d Secondary end point.
980 d CID 2011:53 (15 November) d Phyo et alP 5 .0005). Overall 84.3% of patients (415/492) had P. vivax
gametocytemia evident on their admission blood ﬁlm. By
48 hours, this proportion had fallen to 7.6% (18/238) in the CQ
group and 1.3% (3/239) in the DP group (P 5 .001). Although
all patients had a history of fever (median duration, 2 days) on
admission to the study, only 42.1% (191/454) were febrile at
enrollment. Fever clearance was signiﬁcantly faster in patients
receiving DP; 92.9% (183/197) were afebrile by day 2 compared
with 82.2% (171/208) of those receiving CQ (P 5 .001).
Efficacy Analysis
In the modiﬁed intention-to-treat analysis, the cumulative risk
of recurrence with P. vivax at 9 weeks was 79.1% (95% CI,
73.5%–84.8%) in patients treated with CQ compared with
54.9% (95% CI, 48.2%–61.6%) in those receiving DP (HR, 2.27;
95% CI, 1.8–2.9; P , .001) (Table 2). This signiﬁcant difference
had already emerged by day 28 of follow-up and was conﬁrmed
at both day 28and day 63 in the per-protocol population(Table 3
and Figure 2). By day 28, recurrent infections had emerged in
8.7% CQ recipients (18/207) compared with 2.2% (5/230)
treatedwithDP(relativerisk,4.0;95%CI,1.51–10.58;P5 .005).
The median time to recurrence of P. vivax infection was 56 days
(interquartile range [IQR], 42–56; range, 14–65) in the DP
group compared with 42 days (IQR, 35–49; range 19–66) in the
CQ group (P , .001). Falciparum malaria was also more
A
B
Figure 2. A, Cumulative risk of treatment failure in patients with Plasmodium vivax parasitemia (P. vivax alone or mixed infections). Diamonds
represent chloroquine (CQ); circles, dihydroartemisinin-piperaquine (DP). The overall difference between treatment groups at day 63 was significant
(P ,.001). B, Cumulative risk of treatment failure in patients with Plasmodium falciparum parasitemia (P. falciparum infection alone or mixed infections).
The overall difference between treatment groups was significant at day 28 (P 5 .015) but not by day 63 (P 5 .176).
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and 15 in the CQ group were parasitemic with P. falciparum
(either alone or mixed with P. vivax) (HR, 3.1; 95% CI, 1.2–7.9;
P 5 .015). These ﬁgures had increased to 13 and 21, respectively,
by day 63, although this difference was no longer signiﬁcant in
the modiﬁed intention-to-treat analysis (Table 2). Recurrent
malaria within 28 days (both P. vivax and P. falciparum) was
therefore 6.11 (95% CI, 2.61–14.29) times more frequent in CQ
recipients than in DP recipients.
Cox regression analysis (modiﬁed intention-to-treat pop-
ulation) revealed 2 independent baseline factors predicting
recurrent P. vivax infection: treatment with CQ (adjusted HR
[AHR], 2.3; 95% CI, 1.8–2.9; P , .001) and young age
(1–4 years) (AHR, 1.58; 95% CI, 1.1–2.2; P 5 .005 for com-
parison with older children and adults). In addition, patients
treated with CQ who had delayed parasite clearance (still
parasitemic on day 2), were at signiﬁcantly greater risk
of recurrent P. vivax infection by day 28 (23.5%; 95% CI,
9.2%–37.8%) compared with 6.5% (95% CI, 2.4%–10.6%) in
patients whose initial parasitemia had cleared within 48 hours
(P 5 .004). This difference remained signiﬁcant after age and
baseline parasitemia were controlled for (AHR, 4.2; 95% CI,
1.6–11.1; P 5 .004).
The minimum effective plasma concentration (MEC) of
combined CQ plus desethylchloroquine considered effective
against CQ-susceptible parasites is 12 ng/mL [1, 19]. Of 156
recurrences of P. vivax infection in the CQ group, plasma
concentrations of CQ and desethylchloroquine were de-
termined in 85 patients (54%). In the 5 patients with
recurrence before day 28, these plasma concentrations at the
time of failure were 4.59, 5.00, 5.00, 7.50, and 15.5 ng/mL. The
patient with a plasma CQ-desethylchloroquine concentration
of 15.5 ng/mL (higher than the MEC of 12 ng/mL) had
treatment failure at day 21.
Symptoms and Tolerability
Early vomiting within the ﬁrst hour of drug administration was
recorded in 7.9% of patients treated with DP (19/241) and 7.1%
of those treated with CQ (17/241) (P 5 .86). With the exception
ofthe 3-year-oldboyintheCQgroup,allpatientstolerateddrug
readministration (Figure 3). The only signiﬁcant difference be-
tween the 2 treatment arms in the development of symptoms
wasa4.0-fold(95%CI,1.5–11.3-fold)increasedriskofvomiting
on days 1 and 2 associated with CQ; 10.5% of patients receiving
CQ (22/209) vomited, compared with 2.8% (6/211) of those
receiving DP (P 5 .003). The risk of diarrhea was 0.2% in both
treatment arms assessed at day 7. No serious adverse event
occurred during the study.
Parasite In Vitro Drug Susceptibility
CQ susceptibility was assessed in 50 isolates before administra-
tion of antimalarial medication, of which 43 had a majority of
ring stages present. Drug susceptibility could be assessed suc-
cessfully in 86% of these isolates (37/43). The median inhibitory
concentration (IC50) for CQ was 27.4 ng/mL (IQR, 11.8–46.1l;
range, 3.4–124.8) and 51.7 ng/mL (IQR, 45.3–69.3; range, 12.5–
121.7) for piperaquine (Figure 4). In total, 13.5% of isolates
(5/37) had CQ IC50 values .50 ng/mL (100 nmol/L).
Figure 3. Adverse events on day 1 or 2 in patients without symptoms at admission.
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An estimated 2849 million persons are at risk of P. vivax infection
[20], with between 76 and 391 million clinical cases per year. The
efﬁcacy of CQ, the drug used to treat vivax malaria for .50years,
has fallen insome areas, and resistance seemsto be spreading. The
assessment of treatment efﬁcacy in P. vivax is more difﬁcult than
in P. falciparum, because there are no genotyping methods that
reliably distinguish relapses from new infections, and long-term
cultures of P. vivax cannot be maintained, thereby conﬁning in
vitro testing of drugs to assays on fresh isolates. This means that it
is difﬁcult to document unequivocal cases of treatment failure in
areas where resistance is emerging, but any P. vivax infection that
occurs within 28 days after the start of CQ treatment, whether
recrudescence, relapse, or new infection, has grown through re-
sidual CQ concentrations in blood. If these concentrations are
adequate, then the infection is resistant, by deﬁnition [21].
In this study we assessed the in vivo efﬁcacy of CQ and
compared it with that of DP, an artemisinin combination
therapy with documented efﬁcacy against CQ-resistant P. vivax
[5, 22, 23]. More than 8% of patients treated with CQ had
a recurrent infection within 28 days, and this rate rose to 22% in
young children. Parasite and fever clearance times were both
signiﬁcantly faster after DP treatment. The artemisinin de-
rivatives are the most rapidly acting drugs against P. vivax [17],
so this difference is expected. The artemisinin component of DP
contributes signiﬁcantly to the initial therapeutic response but
would not be expected to affect subsequent relapses or re-
infections. Parasite clearance time was prolonged after CQ
treatment, with 16% of patients still parasitemic at 48 hours and
2% at 76 hours. Delayed parasite clearance, as deﬁned by par-
asitemia on day 2, increased the subsequent risk of recurrent
P. vivax infection within 28 days by almost 4-fold after CQ
treatment. Interestingly, patients who had schizonts in the
peripheral blood on admission had signiﬁcantly slower parasite
clearance after CQ treatment. This presumably reﬂects
uninterrupted schizogony and is consistent with in vitro ob-
servations showing marked reduction in activity of CQ against
these stages [24]. As expected, children who have less natural
immunity against malaria were more at risk of parasite re-
currence independent of the above-mentioned risk factors.
Duringfollow-up,theriskofrecurrenceofP.vivaxinfectionwas
signiﬁcantly greater after CQ than after DP treatment
(AHR, 2.3), a difference that was already apparent by day 28.
Recurrences can result from recrudescence, reinfection, or
relapses from dormant liver stages, although we were unable to
distinguish between these. Both CQ and DP have long elimi-
nation phases and therefore persistent blood concentrations,
delaying the time to the ﬁrst relapse. In areas where CQ sensitive
parasitespredominate,theprolonged posttreatmentprophylaxis
ofCQusuallyaffords aminimum of28dayswithout recurrence.
In the current study the main difference in the parasitologic
response between CQ and DP was evident within this period,
with nearly 9% of patients treated with CQ having a recurrence
by day 28. This ﬁgure is 3 times higher than in our previous
study in 1996, but one-third of that reported from neighboring
Myanmar [7]. In addition, in 1 of these early recurrences
Figure 4. Ex vivo drug susceptibility to chloroquine and piperaquine.
IC50, median inhibitory concentration.
Table 3. Risk of Treatment Failure: Per-Protocol Analysis
Patients with recurrence, % (no.)
Recurrence DP treatment CQ treatment Odds ratio (95% CI)
Plasmodium vivax
Day 63
a 55.1 (113/205) 80.3 (155/193) 3.3 (2.1–5.3) (P , .001)
Day 28
a 2.2 (5/230) 8.7 (18/207) 4.3 (1.5–13.5) (P 5 .005)
Plasmodium falciparum
Day 63
b 10.1 (13/129) 29.6 (21/71) 3.8 (1.6–8.7) (P , .001)
Day 28
b 0.4 (1/228) 7.0 (15/215) 17.0 (2.3–349) (P , .001)
Abbreviations: CI, conﬁdence interval; CQ, chloroquine; DP, dihydroartemisinin-piperaquine.
a Excludes all patients with protocol violations or incomplete follow-up due to P. falciparum parasitemia before day 61 (for day 63 risk) or 26 (for day 28 risk).
b Excludes all patients with protocol violations or incomplete follow-up due to recurrent P. vivax parasitemia before day 61 (for day 63 risk) or 26 (for day 28 risk).
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concentration (15.5 ng/mL) was higher than the MEC of 12 ng/
mL, demonstrating recurrence through drug levels that would
be expected to inhibit CQ-sensitive parasites [1, 19]. In the latest
published study in the same area, primaquine was administered
with CQ, which may have masked the emergence of recurrences
by day 28 [25]. In the present study, the confounding effect of
primaquine asexual stage activity was avoided by adminis-
tering the drug at the end of the follow-up period, to focus
solely on evaluating the main schizontocidal drugs. Associated
in vitro results highlight the fact that whereas the IC50 values
for CQ were generally low (median, 27.4 ng/mL), some iso-
lates exhibited relatively high values. Drug susceptibility
testing was performed only in a small proportion of patients,
and hence our study was underpowered to assess the in vivo–
ex vivo correlates. However, in the parasites that could be
tested, 13% of isolates had reduced susceptibility to CQ
(IC50 .100 nmol/L), in keeping with the overall 9% risk of
recurrence within 28 days.
In conclusion our results suggest that CQ efﬁcacy on the
Northwestern border of Thailand is declining. DP is a suitable
alternative in the treatment of P. vivax infections in this area,
although further studies are needed to deﬁne how best to combine
this treatment with appropriate antirelapse therapy (primaquine).
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